Connor, Clark & Lunn Investment Management (CC&L)
ALLO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Allogene Therapeutics ALLO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Buy
113,964
+74,183
+186% +$149K ﹤0.01% 1431
2025
Q4 		$54.5K Buy
+39,781
New +$52.5K ﹤0.01% 1498
2022
Q3 		– Sell
-46,106
Closed -$526K – 1097
2022
Q2 		$526K Buy
+46,106
New +$409K ﹤0.01% 764

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ALLO Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Allogene Therapeutics (ALLO) stake by 186% in Q1 2026, buying an estimated $149K and bringing the position to 113,964 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1431.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALLO in Q2 2022 and has held it in 3 quarters since. The position peaked at $526K in Q2 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 113,964 shares of Allogene Therapeutics worth $278K as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 74,183 Allogene Therapeutics shares in Q1 2026, an estimated $149K.
  • Allogene Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1431 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Allogene Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Allogene Therapeutics position peaked at $526K in Q2 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.